EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Innovative therapies for inherited retinal dystrophies: navigating DNA, RNA, and protein approaches

Ana Pilar Gómez-Escribano, Gema García-García, Estela Pérez-Santamarina, Elena Aller-Mañas, Rafael Pascual Vázquez-Manrique, José María Millán-Salvador

eBioMedicine · 2025

DOI: 10.1016/j.ebiom.2025.105751 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift eBioMedicine, 2025. Verfasst von Ana Pilar Gómez-Escribano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular, Cellular and Genomic Biomedicine, Instituto de Investigación Sanitaria La Fe, Valencia, Spain; Centro de Investigación Biomé…. Hauptthemen laut MEDLINE: Retinal Dystrophies, Genetic Therapy, RNA, DNA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Valencia Department of Education Culture and Sport, Instituto de Salud Carlos III, Biomedical Research Network Centre of Bioengineering Biomaterials and Nanomedicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gene therapy has become a promising treatment for inherited retinal dystrophies (IRDs), but understanding the genetic mechanisms involved is essential for its success. Various approaches, such as gene augmentation and DNA/RNA-based therapies, have shown effectiveness in some clinical trials. However, gene augmentation is not effective for some dominant mutations and genome editing produces off-target effects. Here, we review safer and viable alternatives that are being evaluated in preclinical models and clinical trials to address this challenge. We propose a novel perspective based on protein-targeting therapies, which although promising, remain unexplored. We suggest that frameshift variants, which produce novel epitopes, may allow for the development of mutant protein targeting agents for selective protein degradation. This approach could be useful for dominant variants, where gene replacement is ineffective. By examining these approaches, we aim to guide more targeted and effective gene therapies for IRDs, offering potential treatments where current methods fall short.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinal DystrophiesGenetic TherapyRNADNAHumansGene EditingAnimalsMutation

Stichwörter der Autor:innen

DNA and RNA editingGene therapyInherited retinal dystrophiesProtein degradersSplicing modulators

Substanzen

RNADNA

Autor:innen und Institutionen

  • Laboratory of Molecular, Cellular and Genomic Biomedicine, Instituto de Investigación Sanitaria La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain; Joint Un…
  • Centenara labs, Zürich, Suiza, Switzerland.

Förderung

  • Valencia Department of Education Culture and Sport
  • Instituto de Salud Carlos III
  • Biomedical Research Network Centre of Bioengineering Biomaterials and Nanomedicine
  • European Regional Development Fund

Zitieren

APA

Gómez-Escribano, A. P., García-García, G., Pérez-Santamarina, E., Aller-Mañas, E., Vázquez-Manrique, R. P., & Millán-Salvador, J. M. (2025). Innovative therapies for inherited retinal dystrophies: navigating DNA, RNA, and protein approaches. eBioMedicine. https://doi.org/10.1016/j.ebiom.2025.105751

Vancouver

Gómez-Escribano AP, García-García G, Pérez-Santamarina E, Aller-Mañas E, Vázquez-Manrique RP, Millán-Salvador JM. Innovative therapies for inherited retinal dystrophies: navigating DNA, RNA, and protein approaches. eBioMedicine. 2025. doi:10.1016/j.ebiom.2025.105751

BibTeX
@article{GmezEscribano2025,
  author = {Gómez-Escribano, Ana Pilar and García-García, Gema and Pérez-Santamarina, Estela and Aller-Mañas, Elena and Vázquez-Manrique, Rafael Pascual and Millán-Salvador, José María},
  title = {Innovative therapies for inherited retinal dystrophies: navigating DNA, RNA, and protein approaches},
  journal = {eBioMedicine},
  year = {2025},
  doi = {10.1016/j.ebiom.2025.105751}
}
Kostenlos starten →